Partnership to maximise insights from shape-based chemistry and generate novel drug candidates in neurodegeneration
29 November 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a drug discovery partnership with GTN Ltd. (“GTN”), a disruptive new player in the field of drug discovery artificial intelligence (“AI”), initially focussing on identifying potential small molecule hits against a high-value neurodegeneration target.
“Manchester based C4X Discovery celebrated the only double win on the night, achieving the Bionow Project of the Year award for the development of Orexin-1 Receptor Antagonists for the Treatment of Addiction, while its Lead Software Developer Phil Muwanga won in the prestigious Promising Technologist of the Year category. Phil is applying gaming technology and virtual reality to revolutionise the drug discovery industry allowing scientists to visualise how drugs interact with our bodies at the molecular level…"
27 November 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a discovery partnership with LifeArc®, one of the UK’s leading medical research charities. C4XD and LifeArc will join forces to progress medicinal chemistry efforts on a novel, commercially attractive programme with applicability across oncology and inflammation indications. The undisclosed target originated from LifeArc’s extensive partnerships in early-stage academic research.
Taking a patient-centered approach, Indivior is developing innovative treatments for addiction to opioids, alcohol, and stimulants, as well as accompanying illnesses such as schizophrenia.
...selective blockade of the OX1 receptor decreases drug seeking and prevents relapse or reinstatement of drug-seeking behavior during abstinence in animal models of addiction. Indivior has entered into a partnership with C4X Discovery to develop their lead molecule, C4X3256, a selective OX1 receptor antagonist.
Drug development company C4X Discovery is using the same technology used to build the incredibly popular Fortnite video game to develop medicines in the digital world that it hopes can make an impact in the real world.
‘Pop into the labs of Manchester biotech C4X Discovery and you could be in for a surprise. Instead of scientists perched at their work stations peering down microscopes or poring over data, you might find them walking around, arms outstretched, holding what would appear to be imaginary objects.
These scientists haven’t gone mad. They’re pioneers of a new field in drug discovery that combines science with the sort of virtual reality technology typically associated with gaming. Using a headset and hand controls they’re transported into 3D chambers where they can access a database of virtual molecules to pull and twist to see how they fit together.’